DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.
Sign in and take the values quiz to see how this bill lines up with what you've said.
This bill amends Medicare Part B payment rules for certain cancer and complex therapy drugs subject to federal price negotiation. It establishes a rebate mechanism where drug manufacturers must pay rebates to Medicare when the negotiated maximum fair price (MFP) is lower than the standard ASP+6 payment amount, with the rebate amount calculated based on the difference between these prices multiplied by the number of units dispensed. The bill also adjusts beneficiary coinsurance to be based on the MFP+6 amount rather than ASP+6, and deposits manufacturer rebates into the Medicare Supplementary Medical Insurance Trust Fund.
Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.
Sign in to see how your representatives voted on this bill.